Executive analysis

Pharmacy news and analysis for healthcare leaders

Clear, practical writing for leaders responsible for pharmacy economics, payer relationships, contracting, compliance, reimbursement, and enterprise risk.

Selected analysis and practical resources. Each article shows its publication or update date and links to the underlying sources.

Chad Frost writing at a desk in a navy suit

Pharmacy Reimbursement • Professional Dispensing Fee • PBM Regulation • Arkansas

Arkansas Reports $10.50 Generic Dispensing Fee Across About 1,052 Plans

Arkansas’s Insurance Department reports that the $10.50 additional cost to dispense generic medications has been implemented across approximately 1,052 health benefit plans, compared with approximately 100 in October. Its report dated November 20 also identifies pending plan appeals. These figures concern Arkansas’s reimbursement framework and do not establish a nationwide payment requirement. Chad’s analysis: the expansion provides a practical example of separating drug acquisition reimbursement from payment for dispensing services, while actual entitlement and payment still require plan-specific verification.

November 20, 20261 min read
Read the analysis

Louisiana • Pharmacy Records • Pharmacy Compliance • Controlled Substances

Louisiana Revises Pharmacy Record Retrieval and Filing Rules

Louisiana’s pharmacy rule changes took effect November 20, according to the Board’s regulatory-project record. The published text expressly requires searches by patient, prescriber, drug and dispensing date, with immediate printed and downloadable electronic retrieval. It also allows date-sequence filing and revises identification and imaging provisions. The two-year retention obligation already existed. Chad’s analysis: pharmacies should test their software and record-production procedures against the revised language, while preserving applicable federal controlled-substance requirements.

November 20, 20262 min read
Read the analysis

Opioid Litigation • Controlled Substances • West Virginia • Pharmacy Compliance

West Virginia Opioid Recovery Effort Reportedly Fails Again After Appellate Revival

Law360 reports that Judge David Faber again ruled for three opioid distributors on November 18 after the Fourth Circuit vacated their earlier victory. The report describes a failure to prove diversion while the drugs were under the distributors’ control. The appellate court previously allowed West Virginia public-nuisance claims and money-funded abatement to proceed. This article distinguishes the reported outcome from the reviewed appellate record. The new district opinion and any separate judgment remain unreviewed.

November 19, 20262 min read
Read the analysis

HIPAA • Privacy • Pharmacy Compliance • Patient Access

HIPAA’s New 15-Day Access Deadline Calls for Pharmacy Workflow Changes

HHS published its final HIPAA Privacy Rule changes November 19. HIPAA-covered pharmacies will face a 15-calendar-day records-access standard, revised copy-fee requirements and updated privacy notices. The rule also removes the effort to obtain written acknowledgment of notice receipt. The published effective date is January 19, 2027, with general compliance due July 19, 2027. Chad’s analysis: pharmacy leaders should use the transition to align request handling, patient communications and vendor responsibilities.

November 19, 20261 min read
Read the analysis

PBM Regulation • Texas • Pharmacy Ownership • Contracting

Texas Bill Would Bar PBM Control of Licensed Pharmacies

Texas H.B. 1236, filed November 18, would prohibit PBM control or common control of Texas-licensed pharmacies. The proposal reaches ownership and specified contractual arrangements, with license consequences and conditional temporary authorizations. Its operational prohibition would apply January 1, 2028, if enacted. Filing changes no current obligation. Chad’s analysis: the practical question is how the proposed control test would distinguish routine contracting from influence over pharmacy practice. The Board’s implementing criteria would be consequential.

November 19, 20261 min read
Read the analysis

Pharmacist Services • Reimbursement • Tennessee • Patient Access

UnitedHealthcare and CPESN Bring Pharmacy Clinical Care Into a Seven-State Model

UnitedHealthcare and CPESN announced November 18 that their care model is available to Community Plan members in seven states, including Tennessee. Participating independent pharmacies connect patients with clinical support, selected testing and virtual visits. CPESN says the model supports reimbursement for pharmacists’ clinical care. The announcement does not disclose payment rates or contracting terms. Chad’s analysis: the opportunity deserves review, with service revenue evaluated alongside the resources required to deliver care.

November 19, 20261 min read
Read the analysis

FDA • Drug Quality • Supply Chain • Pharmacy Operations

FDA’s New Drug-Quality Initiative Includes Retail Pharmacy Samples

FDA announced its Enhanced Approach for Sampling and Testing on November 18. The agency plans to test drug samples from retail pharmacies and wholesale distributors, using modern screening and traditional methods to assess identity, purity, and potency. Results will guide inspection priorities and possible regulatory action. FDA announced no new pharmacy testing requirement or compliance deadline. Chad’s analysis: pharmacies can review how they retrieve supplier and lot information and handle quality complaints.

November 18, 20261 min read
Read the analysis

Compounding • GLP-1 • Advertising • Pharmacy Litigation

Magistrate Recommends Liability Over Compounded GLP-1 Marketing

A Florida federal magistrate judge recommended that Novo Nordisk prevail on liability against MD Exam over advertising for compounded semaglutide. The November 13 report addresses use of the Ozempic and Wegovy marks, including “oral Ozempic” and a “Wegovy Program.” The recommendation leaves remedies for further proceedings. For pharmacies and telehealth partners, the case offers a concrete reason to review how marketing identifies a compounded product and describes its relationship to an FDA-approved medicine.

November 18, 20261 min read
Read the analysis

Conscience Protections • Pharmacy Litigation • Scope of Practice • Patient Access

Aid-in-Dying Litigation Tests Pharmacists’ Conscience Protections

An Illinois lawsuit brings a pharmacist’s religious objection to aid-in-dying referrals before a federal court. The plaintiffs include Luke Vander Bleek and Fitzgerald Pharmacy. An agreed September order provided temporary protection for specified parties and providers while preserving enforcement against nonparties. The dispute highlights a practical question for pharmacy policies: which information, referral, or records duties may remain when a professional declines participation? The answer requires checking the applicable state law, professional role, and scope of any court order.

November 18, 20262 min read
Read the analysis

FDA • REMS • Pharmacy Operations • Isotretinoin

iPLEDGE Changes Isotretinoin Authorization and Pickup Rules

The iPLEDGE program lists November 15 as the effective date for revised isotretinoin requirements. Under its updated instructions, pharmacists enter the prescriber’s National Provider Identifier to obtain authorization for patients who cannot get pregnant. The program no longer assigns a dispense-by date for that group. The seven-day pickup window continues for patients who can get pregnant. A patient who misses the first window needs a repeat pregnancy test in a medical setting before starting treatment, and the additional waiting period has ended.

November 16, 20261 min read
Read the analysis

FDA • Infusion Pharmacy • Nephrology • Drug Safety

FDA Expands Gazyva’s Label to Primary Membranous Nephropathy

FDA has approved Gazyva, or obinutuzumab, as the first specifically approved treatment to induce proteinuria remission in adults with primary membranous nephropathy who are at risk of progression. Genentech announced the approval November 15. In the trial FDA reviewed, complete remission at 104 weeks was 36% with Gazyva and 6% with tacrolimus. Infusion pharmacists can verify that order sets reflect the kidney indication, including its dosing schedule, hepatitis B screening, and precautions for infusion reactions.

November 16, 20261 min read
Read the analysis

Pharmacy Compliance • Health Care Fraud • Medicare • Medicaid • Florida

Jacksonville Pharmacist Agrees to Plead Guilty in HIV Drug Billing Case

Federal prosecutors said November 12 that Jacksonville pharmacist Albert Chester agreed to plead guilty in a case involving HIV post-exposure prophylaxis prescriptions. The Justice Department describes an alleged $51 million scheme involving payments to marketers when referred prescriptions generated paid insurance claims. Prosecutors also allege that prescriptions were authorized without patient evaluations and claims used unsupported diagnosis codes. The case gives pharmacy owners a reason to review how referrals become prescriptions and how diagnoses supplied with claims are verified.

Updated November 13, 20261 min read
Read the analysis

Alabama • Pharmacy Licensure • Pharmacy Technicians • Military Families

Alabama Proposes a Faster Pharmacy Licensing Process for Military Families

The Alabama State Board of Pharmacy proposes a formal, fee-free initial application process for qualified pharmacists and pharmacy technicians who relocate under military orders as servicemembers or their spouses. Eligible applicants would need a qualifying license in good standing and documentation of the move. The Board’s executive secretary would issue licenses on completed applications without a separate Board vote. Written comments are due by close of business November 17, and the Board will hold a public hearing November 18 at 9 a.m. Central in Birmingham.

Updated November 13, 20261 min read
Read the analysis

FTC • Health Privacy • Telehealth • Pharmacy Fulfillment • Consumer Protection

Five States Join FTC’s Hims & Hers Privacy and Billing Suit

The FTC filed an amended complaint November 10 in federal court in Northern California. Arizona, Florida, Nebraska, Ohio, and Wisconsin joined the existing plaintiffs and added claims under their consumer protection laws. The case alleges that Hims & Hers shared sensitive information about treatment interests with advertising platforms and misled consumers about prescription charges and cancellation. The allegations remain pending. Pharmacies that fulfill prescriptions for online platforms can review what their partners disclose at intake, when payment is authorized, and which vendors receive patient information.

November 11, 20262 min read
Read the analysis

FDA • GLP-1 • Drug Safety • Vision Loss • Pharmacy Counseling

FDA Requires Class-Wide GLP-1 Warning for Rare Vision Loss

FDA is requiring a class-wide GLP-1 labeling warning for a possible increase in nonarteritic anterior ischemic optic neuropathy, a rare condition that can permanently impair vision. FDA’s pooled trials found 6.4 cases per 100,000 person-years with GLP-1 therapy versus 3.8 in comparison groups. Reduced blood flow injures the optic nerve, but how these drugs might contribute remains uncertain. The evidence cannot yet identify who should switch or which drug would lower that risk. FDA advises immediate reporting of sudden vision changes in one eye and prompt ophthalmology referral when NAION is suspected.

November 10, 20262 min read
Read the analysis

DEA • Controlled Substances • Drug Supply • Pharmacy Operations

DEA’s Higher 2026 Production Quotas Take Effect

DEA’s final order took effect November 10 when it appeared in the Federal Register. It raises the national production quotas for two amphetamine categories, hydromorphone, and methylphenidate for sale. The published figures match the order made available for public inspection on November 9. DEA separately published proposed 2027 quotas, with comments due December 10 at 11:59 p.m. Eastern for electronic filings. The higher 2026 limits allow additional production. Pharmacy teams can track whether availability improves by strength, package, and supplier.

November 10, 20261 min read
Read the analysis

North Carolina • Scope of Practice • Collaborative Practice • Pharmacy Operations

North Carolina Takes Comments on Clinical Pharmacist Practice Rules

North Carolina’s pharmacy and medical boards scheduled a joint hearing for November 10 on rules for clinical pharmacist practitioners. The proposals implement a 2025 law that expanded physician-delegated services and authorized site-specific agreements for institutions and group practices. The drafts specify required agreement terms and would set annual practice-relevant continuing education at 25 hours. Written comments are due December 14, and the boards list April 1, 2027, as the proposed effective date. Practices can use the comment period to flag provisions that may be difficult to implement.

November 10, 20261 min read
Read the analysis

PBM • Medicare Part D • Reimbursement • Contracting

CMS Corrects the Comment Docket for Its Part D PBM Proposal

CMS published a correction on November 9 directing electronic comments on its Medicare Part D PBM proposal to docket CMS-2026-3533. The October 20 notice listed CMS-2026-2533. Comments remain due December 15, 2026, at 5 p.m. Eastern Standard Time. The correction concerns where to file. The compensation, reporting, and sponsor oversight provisions remain proposed. Pharmacies preparing comments can use the corrected docket and save the submission confirmation with their comment materials.

Updated November 9, 20261 min read
Read the analysis

Compounding • GLP-1 • Consumer Protection • Litigation

Proposed Consumer Class Action Challenges Empower’s Compounded GLP-1 Marketing

A newly accessible October 30 complaint in New Jersey federal court alleges that two Empower entities misled consumers about the clinical evidence, personalization, and quality of compounded semaglutide and tirzepatide. The plaintiffs bring state-law claims and seek class certification, corrective advertising, and monetary relief. The complaint states the plaintiffs’ allegations. Both defendants filed waivers of service November 6, and the public docket lists January 4, 2027, as their answer deadline. The filing gives pharmacy and telehealth teams a reason to review whether their marketing claims describe the formulation patients actually receive.

November 9, 20261 min read
Read the analysis

Medicare Part D • Reimbursement • Network Access • Patient Access • Professional Dispensing Fee

MedPAC’s First Pharmacist Focus Groups Examine Reimbursement and Drug Access

MedPAC staff presented preliminary findings from the commission’s first pharmacist focus groups on November 6. Participants described how reimbursement affected stocking decisions, how prior authorization delayed some fills, and how preferred-network status shaped what patients paid. The small, qualitative study describes participant experiences. Those accounts give practical context to a question Chad Frost and Asher Jackson Frost examine in their commentary accepted by the Journal of the American Pharmacists Association. Does the professional dispensing fee reflect the work needed to dispense a prescription safely?

November 9, 20262 min read
Read the analysis

PBM • Pharmacy Contracting • Network Access • Reimbursement • Competition

CVS Plans to Separate Retail and Mail Pharmacy From Caremark

CVS Health announced on November 4 that it plans to create two public companies, targeting the first half of 2028. The standalone CVS Pharmacy would include retail and mail pharmacy, MinuteClinic, and Health100. Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health would stay together. CVS says it will continue operating as it does today until closing. For pharmacy operators, the next details to watch are how the companies contract with each other and whether any network or reimbursement terms change.

November 4, 20262 min read
Read the analysis

PBM • Antitrust • Reimbursement • Florida • Litigation

Express Scripts Moves Florida Pharmacy Reimbursement Suit to Federal Court

Express Scripts filed a notice of removal on November 2 in Florida’s reimbursement case against the company and Prime Therapeutics. Florida alleges the PBMs’ 2019 agreement suppressed retail pharmacy reimbursement. Express Scripts denies the allegations and argues that the challenged network serves both commercial clients and federal programs, including TRICARE. The filing changes where the case is being litigated while jurisdiction remains open to challenge. It creates no immediate reimbursement change for Florida pharmacies.

November 4, 20261 min read
Read the analysis

DEA • Controlled Substances • Registration • Pharmacy Operations

DEA Clarifies When It Treats a Registration Renewal as Withdrawn

DEA’s final technical amendment, published and effective November 4, expressly applies its application withdrawal provision to registration renewals. After DEA accepts an application for filing, it treats the application as withdrawn if the applicant or registrant asks for it back or fails to respond to official correspondence sent by registered or certified mail with return receipt requested. DEA says it already applied the rule to renewals. Pharmacy operators can use the clarification to check who receives, logs, and responds to renewal correspondence.

November 4, 20261 min read
Read the analysis

340B • Contract Pharmacy • Patient Access • Reimbursement

J&J’s 340B Contract Pharmacy Policy Reaches Grantees November 3

Johnson & Johnson’s September 4 notice sets November 3 as the start date for its contract pharmacy designation policy for affected 340B grantees. The manufacturer generally allows one registered dispensing location within 40 miles of the grantee site, with a separate designation for certain pulmonary arterial hypertension drugs. AIDS Drug Assistance Programs are excluded, and applicable state exceptions are communicated separately. Grantees and their pharmacy partners should verify that the correct dispensing site is active before assuming replenishment will qualify for 340B pricing.

November 3, 20261 min read
Read the analysis

PBM • ERISA • Pharmacy Reimbursement • Transparency • Audit Rights

DOL PBM Disclosure Rule Published; Effective January 4, 2027

DOL’s final PBM disclosure rule was published November 2, establishing January 4, 2027 as its effective date. The detailed requirements apply to plan years beginning on or after July 1, 2027. Covered large self-insured ERISA plans gain compensation disclosures and audit rights. Pharmacy leaders should use the confirmed dates to plan contract reviews while distinguishing a plan’s oversight rights from a pharmacy’s own reimbursement and recoupment remedies.

Updated November 2, 20262 min read
Read the analysis

Compounding • FDA • Drug Safety • Recalls • Pharmacy Operations

FDA Posts a Multi-Product Compounding Recall for Victory Medical Center Pharmacy

FDA posted and classified an ongoing voluntary recall involving Victory Medical Center Pharmacy on October 30. The Austin pharmacy initiated the action October 19. FDA identifies 42 Class II product entries and distribution in Colorado, Florida, and Texas, with lack of processing controls as the stated reason. The records include compounded semaglutide and tirzepatide combinations, peptides, and vitamin preparations. Pharmacies and receiving practices should match the specific product and lot records before acting, rather than treating every preparation from the facility as recalled.

November 2, 20262 min read
Read the analysis

PBM • Maryland • Specialty Pharmacy • Reimbursement • Public Comments

Maryland Seeks Comments on Draft PBM and Specialty Pharmacy Recommendations

Maryland’s insurance and health agencies presented a draft final PBM workgroup report October 30 and are accepting written comments through the end of November 13. The draft recommends studying pharmacy-benefit delivery models, revising specialty-drug and specialty-pharmacy definitions, and publishing specialty-drug lists. It does not adopt new reimbursement rates or impose new pharmacy duties. Pharmacy leaders can use the comment period to address accreditation, network access, and how specialty classifications affect dispensing.

November 2, 20261 min read
Read the analysis

Controlled Substances • DEA • ADHD • Clinical Pharmacology • Pharmacy Operations

Centanafadine Enters Schedule III: ADHD Indication and Place in Therapy

Simtriyo, the brand for centanafadine extended-release capsules, is indicated for ADHD in adults and children aged six years and older weighing at least 20 kg. DEA’s Schedule III rule took effect October 30. Its current fit in therapy may center on patients who might benefit from its combined reuptake activity, an assessment requiring clinical judgment rather than an established responder subgroup. Pharmacists should understand the labeled mechanism, safety information, and controlled-substance handling requirements.

October 30, 20262 min read
Read the analysis

Compounding • Peptides • 503A • FDA • Compliance

HHS Publishes Peptide Policy Notice; Comments Due November 13

HHS’s peptide policy notice was published October 30, making November 13 the end of its two-week comment period. The published notice still calls the underlying policy a draft and states that it is nonbinding. Publication does not establish FDA approval or add the six substances to the final 503A bulks list. This update confirms the public-comment timing while preserving the status qualifications, identity and route limits, and operating conditions described in the earlier analysis.

Updated October 30, 20263 min read
Read the analysis

Medicare Part B • Pharmacy Compliance • Drug Billing • HHS OIG

OIG Flags Medicare Outpatient Drug Coding Gaps

A new HHS OIG data brief identifies gaps in Medicare’s oversight of hospital outpatient drug billing. The review flagged 160,918 claim lines with mismatched drug and procedure codes, but did not establish that their $27.6 million in payments were improper. A nonstatistical sample confirmed coding errors. The findings give hospital pharmacy and billing teams a concrete reason to review drug-code mappings and claim controls, without creating a new regulatory requirement.

October 30, 20261 min read
Read the analysis

Medicare • Pharmacy Quality • Medication Adherence • Administrative Law • Pharmacy Litigation

CVS Challenges Medicare Star Ratings, Including Medication Adherence Measures

CVS Health and its insurer subsidiaries sued HHS and CMS October 26 over the 2027 Medicare Star Ratings. Their complaint challenges the adoption of 28 criteria and the statutory basis for data used in 12. It also questions whether claims-based medication adherence reflects clinical care accurately. CVS projects more than $2 billion in affected 2028 payments. These are litigating positions and estimates. Pharmacy leaders should examine the dispute’s implications for data quality, transparent methods, and review procedures.

October 28, 20262 min read
Read the analysis

340B • Pharmacy Litigation • Massachusetts • Data Privacy • Patient Access

Massachusetts Hospitals Sue Lilly Over 340B Claims Data Requirements

Five Massachusetts hospitals sued Eli Lilly October 27 over claims data requirements tied to 340B pricing. According to their complaint, Lilly withheld discounts after they declined to submit in-house pharmacy and medical claims through 340B ESP. The hospitals assert Massachusetts consumer-protection and unjust-enrichment claims and seek injunctions and monetary relief. These are allegations, not findings. Pharmacy leaders should review purchasing exposure and data-sharing controls. Later docket orders were not verified for this report.

October 28, 20262 min read
Read the analysis

340B • Supreme Court • Mississippi • Contract Pharmacy • State Regulation

Supreme Court Requests Mississippi’s Response in 340B Contract Pharmacy Challenge

On October 27, the Supreme Court requested Mississippi’s response in Novartis v. Fitch, a pending challenge to the state’s 340B contract pharmacy law. The deadline is November 27, 2026. Fitch had waived a response on October 20. Novartis argues that federal law preempts the state’s requirements. The new docket entry advances briefing without granting review, a stay, or other relief. The company’s request for Supreme Court consideration remains pending.

October 28, 20261 min read
Read the analysis

Wisconsin • Medicaid • Prior Authorization • Patient Access • Pharmacy Operations

Wisconsin Moves Generic Buprenorphine Patches to Non-Preferred Status November 1

Wisconsin’s November preferred drug list moves generic buprenorphine patches to non-preferred status, requiring prior authorization, while Butrans remains preferred. The October list temporarily preferred the generic because of Butrans shortage and access issues. The new list takes effect November 1 for Wisconsin Medicaid, BadgerCare Plus Standard, and SeniorCare. Pharmacies should review affected prescriptions and authorization needs before the change. The reviewed documents do not specify how existing approvals will transition.

October 27, 20261 min read
Read the analysis

Compliance • Medicare and Medicaid • Exclusion Screening • OIG

OIG Clarifies Exclusion Screening as CMS Authority Expands

OIG’s October 27 FAQ update says its exclusion list currently contains only OIG actions, while publication arrangements with CMS remain under development. OIG also confirms its continuing role in resolving exclusion exposure in False Claims Act matters. The guidance follows an October 14 delegation notice. Pharmacy compliance leaders should review screening assumptions and escalation procedures without treating the FAQ as a new screening mandate.

October 27, 20261 min read
Read the analysis

PBM • Pharmacy Audits • Congressional Oversight • Enterprise Risk

House Oversight Examines Whether PBM Audits Targeted Pharmacy Advocates

House Oversight Chairman James Comer requested records from CVS Caremark, Express Scripts, and Optum Rx on October 23 concerning possible retaliation against independent pharmacies that supported H.R. 6610. The letters seek audit-selection methods, provider agreements, audit totals, and detailed records for three states. Requested briefings are due October 30 and documents November 6. These requests are directed to the PBMs. The inquiry does not decide whether retaliation occurred. Pharmacy leaders can use the development to review how they document notices, deadlines, communications, and outcomes.

October 26, 20261 min read
Read the analysis

South Carolina • Compounding • Collaborative Practice • Compliance

South Carolina Proposes Compounding and Collaborative-Practice Rules

South Carolina’s Board of Pharmacy published proposed compounding and collaborative-practice rules October 23. The package addresses sterile and hazardous-drug preparation and changes facility-permit training language. Comments are due November 23 at 5 p.m. A December 11 hearing depends on a timely qualifying request. These proposals are not effective. Pharmacy leaders should review current procedures and agreements before preparing their comments.

October 26, 20261 min read
Read the analysis

California • Pharmacy Regulation • Scope of Practice • Compliance

California Opens Comments on Standard-of-Care and Self-Assessment Rules

California opened comments October 23 on proposed rules addressing self-assessments and the statutory standard-of-care model. The Board would repeal duplicative provisions and specified prescriptive furnishing protocols, and explains that self-assessment duties remain in statute. Comments are due December 7. No hearing is scheduled. The proposal follows legislation effective January 1, 2026. Pharmacy leaders should compare the draft with current procedures and distinguish this regulatory cleanup from the earlier statutory change.

October 26, 20261 min read
Read the analysis

Alabama • Pharmacy Regulation • Compliance • Enterprise Risk

Alabama’s Pharmacy Penalty Framework Is Now in Effect

Alabama’s revised pharmacy civil-penalty rule and category-specific schedules took effect October 15, 2026, according to the Board of Pharmacy. The framework uses an advisory calculation based on misconduct, public-health risk, and compliance history, with discretion bounded by the applicable schedule. It does not impose an automatic fine. Pharmacy leaders should review their category’s exposure and preserve records supporting compliance, remediation, and the circumstances of any alleged violation.

October 22, 20261 min read
Read the analysis

Drug safety • Counterfeit medicines • Pharmacy operations

FDA Counterfeit Eye Drop Alert Calls for Stock Checks and Patient Counseling

FDA’s October 16 alert identifies counterfeit over-the-counter eye drops found in Florida and Georgia, with possible distribution elsewhere. Testing found bacterial contamination in two products, although the agency reports no associated adverse events. The warning supports immediate patient counseling and review of suspicious retail stock. FDA provides packaging comparisons and advises retailers to contact the company named on the label. A separate September recall concerns a different issue.

October 22, 20261 min read
Read the analysis

Compounding • Recalls • Veterinary pharmacy • Quality systems

Wedgewood Recall Calls for Veterinary Medication Inventory and Customer Checks

Wedgewood Pharmacy announced a nationwide recall of certain compounded veterinary medications on October 21 after identifying unreliable laboratory testing that could allow potency errors. The FDA-hosted notice directs pharmacies to check inventory, quarantine affected stock and notify customers who received it. Product and lot verification should guide the response. Animal owners with matching preparations should stop use, retain the medication and contact recall services.

October 22, 20261 min read
Read the analysis

Georgia • Prescription Transfers • Controlled Substances • Pharmacy Technicians

Georgia Proposes Changes to Prescription Transfers and Technician CE

Georgia’s Board of Pharmacy has proposed changes to prescription transfers and pharmacy-technician continuing education. Its October notice would consolidate transfer requirements, recognize qualifying transfers of unfilled electronic Schedule II prescriptions, and remove general technician CE while retaining function-specific statutory requirements. These changes are not effective. Written comments must arrive before November 17, 2026, ahead of a November 18 hearing and consideration for adoption.

October 22, 20261 min read
Read the analysis

Antitrust • FTC Enforcement • PBM

Two PBM Settlements, No Precedent

The FTC’s proposed Express Scripts and Caremark orders reshape pharmacy benefit contracting while leaving its standalone Section 5 theory unresolved.

August 7, 20265 min read
Read the analysis

Antitrust • Algorithmic Pricing • Pharmacy

The Algorithm and the Handshake

Two pharmacy reimbursement lawsuits test whether a shared pricing platform or a direct PBM agreement can satisfy Section 1 of the Sherman Act.

August 7, 20265 min read
Read the analysis

Contracting • Leadership • Operations

A PBM Contract Is an Operating System

Pharmacy leaders translate contract language into credentialing, claims, documentation, escalation, and accountability before the first dispute arrives.

August 4, 20263 min read
Read the analysis

Explore focused research on PBM audits and appeals, PBM contracts and network access, pharmacy reimbursement and 340B, compounding and FDA compliance, and PBM regulation, ERISA, and competition.